MedChunk
Medically reviewed

Vaccines Before JAK Inhibitor Treatment: Options and Results

Learn which vaccines to consider before starting JAK inhibitors, when to get them, how well they work, and which vaccines require special precautions.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 14 min read

Before starting a JAK inhibitor, doctors usually recommend checking your vaccination history and getting any needed vaccines. Vaccines can help protect against infections such as shingles, flu, and pneumonia while you take medicine that affects your immune system. Getting vaccinated before treatment may improve your body's response, although some vaccines can also be given safely during treatment.

Why Are Vaccines Important Before JAK Inhibitor Treatment?

Janus kinase (JAK) inhibitors are medicines that reduce certain immune system signals involved in inflammation. They are used for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and some other inflammatory diseases.

Examples include tofacitinib, baricitinib, upadacitinib, and ruxolitinib. These medicines have different approved uses, but they can affect how the body responds to infections.

Because JAK inhibitors change immune activity, some infections may occur more often or become more serious during treatment. Shingles, which develops when the chickenpox virus becomes active again, is a particular concern with several JAK inhibitors.

Vaccination helps prepare the immune system to recognize specific infections. Completing recommended vaccinations before treatment provides an opportunity to build protection before the medicine begins affecting immune responses.

The U.S. National Library of Medicine's DailyMed prescribing information for upadacitinib recommends bringing patients up to date with immunizations before starting treatment, including appropriate chickenpox or shingles vaccination. It also advises avoiding live vaccines during or immediately before treatment.

Vaccination does not eliminate infection risk. However, it is an important part of planning safer long-term treatment.

Which Vaccines Should You Get Before Starting JAK Inhibitors?

The recommended vaccines depend on your age, previous vaccinations, medical conditions, infection risks, and country-specific immunization guidelines.

Not everyone needs every vaccine. A healthcare professional can review your records and identify which doses are missing or due for renewal.

Shingles Vaccine (Shingrix)

The shingles vaccine is an important consideration because JAK inhibitors can increase the risk of herpes zoster, commonly called shingles.

Shingrix is a recombinant, non-live vaccine. It is designed to reduce the risk of shingles and related complications, including long-lasting nerve pain.

According to the Centers for Disease Control and Prevention (CDC), two doses of Shingrix are recommended for adults aged 50 years and older and for immunocompromised adults aged 19 years and older, including people who will become immunosuppressed because of treatment.

The usual schedule is:

  • First dose: Given when vaccination is planned.
  • Second dose: Usually given 2–6 months after the first dose.
  • Shortened schedule: A 1–2 month interval may be used for eligible immunocompromised adults when earlier completion would be beneficial.

People who previously had shingles may still need Shingrix. A history of shingles does not replace the recommended vaccination series.

Since Shingrix is not a live vaccine, it may also be administered during JAK inhibitor therapy when appropriate. However, vaccination before immunosuppression is generally preferred when feasible.

Influenza (Flu) Vaccine

Influenza vaccination helps reduce the risk of seasonal flu and its complications.

An age-appropriate, non-live flu vaccine is generally recommended each flu season. This includes people who are preparing to start or already receiving immunosuppressive medication.

Patients taking JAK inhibitors should generally avoid the live attenuated influenza vaccine administered as a nasal spray. An injectable, non-live vaccine is usually the appropriate option.

Because influenza viruses change over time, previous flu vaccination does not replace the need for seasonal vaccination.

Pneumococcal Vaccines

Pneumococcal vaccines protect against infections caused by Streptococcus pneumoniae bacteria. These bacteria can cause pneumonia, bloodstream infections, and meningitis.

People with certain immune-suppressing conditions or treatments may qualify for pneumococcal vaccination at younger ages than the general population.

The available options include pneumococcal conjugate vaccines and, in some vaccination schedules, a pneumococcal polysaccharide vaccine.

The exact products and number of doses depend on age, previous pneumococcal vaccination, immune status, and current national guidelines. Some people need only one additional dose, while others require a series.

COVID-19 Vaccines

COVID-19 vaccination may be recommended before JAK inhibitor treatment based on current public health guidance and individual risk.

COVID-19 vaccines do not contain live, replicating SARS-CoV-2 virus. They can therefore be considered for people receiving immunosuppressive medicines.

Some immunocompromised people may need an adjusted vaccination schedule. Recommendations can change as vaccines and circulating virus variants evolve, so the current local schedule should be followed.

Hepatitis B Vaccine

Hepatitis B vaccination may be appropriate for adults who have not completed the recommended series, particularly those with increased exposure risks or other reasons for vaccination.

Before prescribing a JAK inhibitor, clinicians may also assess hepatitis B infection status because certain immunosuppressive therapies can be associated with reactivation of an existing infection.

Vaccination prevents new hepatitis B infection but does not treat an infection that is already present. Screening and vaccination serve different purposes.

Other Routine Vaccines

Depending on age and immunization history, additional vaccines may be considered:

  • Tetanus, diphtheria, and pertussis (Tdap or Td) vaccines
  • Human papillomavirus (HPV) vaccine for eligible age groups
  • Hepatitis A vaccine when indicated
  • Meningococcal vaccines for people with specific risk factors
  • Respiratory syncytial virus (RSV) vaccine for eligible adults

These are not all automatically required because someone is starting a JAK inhibitor. The decision should reflect routine vaccination recommendations and personal risk factors.

How Long Before JAK Inhibitor Treatment Should Vaccines Be Given?

Vaccine timing matters because the immune system needs time to respond after vaccination.

The CDC guidance on altered immunocompetence generally recommends giving indicated vaccines before starting immunosuppressive treatment when feasible. It advises an interval of about two weeks after non-live vaccines and four weeks after live vaccines before beginning immunosuppressive therapy.

These intervals are general guidance rather than a reason to delay necessary treatment in every situation.

Timing for Non-Live Vaccines

Non-live vaccines include Shingrix, injectable influenza vaccines, pneumococcal vaccines, hepatitis B vaccines, and currently used non-live COVID-19 vaccines.

Whenever practical, healthcare professionals may arrange these vaccinations at least two weeks before the planned start of JAK inhibitor therapy.

However, a person does not always need to complete every dose in a multi-dose series before starting treatment. The clinician may decide that beginning therapy and completing vaccination later offers the most appropriate balance.

Timing for Live Vaccines

Live attenuated vaccines contain weakened forms of living organisms. They are generally avoided during significant immunosuppression because of potential safety concerns.

Examples include:

  • Measles, mumps, and rubella (MMR) vaccine
  • Varicella (chickenpox) vaccine
  • Live attenuated influenza nasal spray
  • Yellow fever vaccine
  • Certain other live vaccines used for specific indications

When a live vaccine is needed before JAK inhibitor treatment, clinicians generally plan an interval of at least four weeks before starting immunosuppression.

Patients who are already receiving JAK inhibitors should not stop their medicine independently to receive a live vaccine. Any interruption requires individualized medical planning.

Can You Get Vaccinated While Taking a JAK Inhibitor?

Yes. Many non-live vaccines can be given during JAK inhibitor treatment, although the immune response may be lower than it would have been before treatment.

The American College of Rheumatology vaccination guideline recommends continuing most immunosuppressive medications, including JAK inhibitors, around non-live vaccination for patients with rheumatic and musculoskeletal diseases. It also generally recommends against live attenuated vaccines during immunosuppressive treatment.

For patients with rheumatic diseases who must receive a live vaccine, the guideline describes specialist-managed medication interruption strategies. These are not instructions for patients to stop treatment themselves and may not apply to every condition treated with JAK inhibitors.

If a vaccine becomes due after treatment has started, the prescribing specialist and vaccination provider can decide how and when it should be given.

Missing an ideal pre-treatment vaccination window does not mean vaccination has no value.

How Effective Are Vaccines Before JAK Inhibitor Treatment?

Vaccines given before immunosuppressive treatment can help the immune system develop protection while its response is less affected by medication.

However, vaccine effectiveness depends on several factors, including the vaccine itself, age, underlying medical conditions, prior immunity, and other medicines being taken.

What Results Can Patients Expect?

There are several possible benefits from vaccination before JAK inhibitor treatment:

  • Lower infection risk: Vaccination may reduce the chance of developing the infection it targets.
  • Fewer complications: Some vaccines help reduce serious outcomes even when they do not prevent every infection.
  • Better immune response: Vaccination before immunosuppression may produce a stronger response than vaccination during treatment.
  • Improved continuity of care: Preventing infections may reduce some infection-related disruptions to ongoing treatment.

These are potential benefits, not guaranteed results. Vaccines do not protect against every infection associated with JAK inhibitor therapy.

What Do We Know About Shingles Vaccine Results?

Shingrix has demonstrated protection against shingles in studied populations, including certain immunocompromised groups. However, the degree of protection may differ according to the medical condition and treatment.

The CDC clinical guidance for immunocompromised adults recommends vaccination before immunosuppression when possible. If that is not possible, it advises choosing a period when the immune response is expected to be strongest.

Research specifically measuring long-term protection in every group of JAK inhibitor users remains limited. Results from one immunocompromised population should not automatically be assumed to apply to every patient taking a JAK inhibitor.

Does a Good Antibody Response Guarantee Protection?

No. Antibodies are one part of the immune system's response to vaccination.

Some studies measure vaccine responses through antibody levels, while others examine actual infections and complications. These results answer different questions.

A measurable antibody response can suggest that the immune system recognized the vaccine, but it does not always predict exactly how well an individual will be protected.

Routine antibody testing after every vaccination is not generally required. Testing may be appropriate for selected vaccines or medical situations when established guidance recommends it.

What Side Effects Can Occur After Vaccination?

Most expected vaccine side effects are temporary and reflect the body's response to vaccination.

Depending on the vaccine, examples can include:

  • Pain, redness, or swelling at the injection site
  • Fatigue or tiredness
  • Headache
  • Muscle aches
  • Temporary fever or chills
  • General discomfort for a short period

Shingrix can cause noticeable short-term reactions in some people, particularly fatigue, muscle pain, and injection-site discomfort.

These effects commonly improve within a few days. Their absence does not mean the vaccine failed to work.

Serious allergic reactions are rare but require immediate medical attention. Warning signs can include difficulty breathing, swelling of the throat or tongue, or sudden faintness shortly after vaccination.

Anyone who has experienced a serious reaction to a previous vaccine should discuss that history with the vaccination provider before receiving another dose.

What If Your Vaccinations Are Incomplete When Treatment Is Due?

Sometimes JAK inhibitor treatment is needed before every recommended vaccine can be completed.

For example, someone with active inflammatory disease may need treatment promptly, while a two-dose vaccine series may take several weeks or months to finish.

In this situation, the treating clinician may recommend starting treatment after an initial vaccine dose, completing non-live vaccination during treatment, or adjusting the timing according to disease activity and infection risk.

The decision should consider:

  • How urgently the inflammatory condition needs treatment
  • Which vaccines have already been received
  • Whether the remaining vaccine is live or non-live
  • Other medicines that affect the immune system
  • Age, previous infections, and current infection risks

A delayed vaccine dose does not necessarily mean the entire vaccine series must be restarted. The appropriate approach depends on the vaccine's dosing recommendations.

Do Vaccine Recommendations Change With Age?

Age can affect both vaccine eligibility and scheduling.

Adults aged 19–49: People who are or will become immunosuppressed may qualify for Shingrix even though routine shingles vaccination in otherwise healthy adults generally begins at age 50 in the United States.

Adults aged 50 and older: Routine shingles vaccination is recommended. Other age-related vaccines, including pneumococcal and RSV vaccines, should be reviewed according to current recommendations.

Children and adolescents: Some JAK inhibitors are approved for specific pediatric conditions. Vaccination planning should follow the child's age-specific immunization schedule and the advice of the prescribing specialist. Adult shingles vaccine recommendations should not automatically be applied to children.

Vaccine approvals and schedules differ between countries, so local guidance is important.

How to Prepare for a Vaccination Review Before Treatment

A pre-treatment visit is a useful time to confirm vaccination history and plan any missing doses.

Bring available vaccination records and a complete list of current medicines, especially corticosteroids, biologic therapies, or other immunosuppressants.

It may help to ask your healthcare professional:

  • Which vaccines are recommended for my age and medical condition?
  • Do I need the shingles vaccine before starting treatment?
  • Are any of my missing vaccines live vaccines?
  • How long should I wait between vaccination and starting my medicine?
  • Can I complete a vaccine series after treatment begins?
  • Will my other medications affect vaccine timing?

If vaccination records are incomplete or uncertain, the healthcare professional can determine whether additional vaccination or selected testing is appropriate.

What Is the Most Important Takeaway?

Reviewing vaccinations before starting a JAK inhibitor can help reduce preventable infection risks during treatment.

Shingles, influenza, pneumococcal, COVID-19, and other routine vaccines may be appropriate depending on age, health history, and current recommendations. Non-live vaccines are generally preferred during immunosuppressive treatment, while live vaccines require special planning.

When possible, vaccination should be completed before starting treatment, but necessary medical care should not automatically be delayed to finish every vaccine series.

A coordinated plan between the prescribing specialist and vaccination provider offers the best way to balance infection prevention with timely treatment of the underlying condition.

Frequently Asked Questions

Common questions about vaccine safety, timing, and protection before JAK inhibitor therapy.

Do I need the shingles vaccine before taking a JAK inhibitor?

Shingrix is recommended for many adults who are or will become immunosuppressed, including eligible people preparing for JAK inhibitor treatment. In the United States, the CDC recommends it for immunocompromised adults aged 19 and older. Your healthcare professional can confirm eligibility and timing based on your medical history and local guidelines.

Can I start a JAK inhibitor after only one Shingrix dose?

Sometimes. Although two doses are recommended, a clinician may decide that treatment should begin before the second dose is due. The remaining dose can be scheduled appropriately. The decision depends on treatment urgency and the expected immune response.

Are COVID-19 and flu vaccines safe while taking JAK inhibitors?

Non-live COVID-19 and influenza vaccines can generally be administered during JAK inhibitor therapy. Immune responses may be reduced in some patients, but vaccination can still provide protection. The live influenza nasal spray is generally avoided during significant immunosuppression.

Should I stop my JAK inhibitor before getting vaccinated?

Usually not for non-live vaccines. Guidance for rheumatic diseases generally supports continuing JAK inhibitors during these vaccinations. Live vaccines require a different approach and may involve a specialist-managed treatment interruption. Never stop a prescribed JAK inhibitor without medical advice.

Will vaccines work less effectively after I start a JAK inhibitor?

Some vaccine responses may be weaker during immunosuppressive treatment, but this does not mean vaccines stop working. Protection depends on the vaccine, underlying condition, other medicines, and individual immune response. Vaccination before treatment is preferred when practical, but recommended non-live vaccines may still be useful after treatment begins.

Citations

  1. DailyMed, U.S. National Library of Medicine — RINVOQ (Upadacitinib) Prescribing Information
  2. Centers for Disease Control and Prevention — Shingles Vaccine Recommendations
  3. Centers for Disease Control and Prevention — Altered Immunocompetence: General Best Practice Guidelines for Immunization
  4. American College of Rheumatology — 2022 Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
  5. Centers for Disease Control and Prevention — Clinical Considerations for Shingrix Use in Immunocompromised Adults Aged 19 Years and Older
Share this article